MedTrace Logo

Safety And Tolerability Of Gamma Glutamylcysteine (GGC) Oral Supplementation In MCI Patients

NCT07583251 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2026-05-13

No results posted yet for this study

Summary

The goal of this study is to evaluate the safety and tolerability of Gamma Glutamylcysteine (GGC) supplement at different doses (400mg/day or 800mg/day or 1200mg/day) when administered orally to patients with MCI over 3 months. This study is designed to generate preliminary clinical safety data to inform the feasibility and design of larger controlled trials.

Conditions

  • Mild Cognitive Impairment (MCI)

Interventions

DRUG

Gamma- Glutamylcysteine

400mg capsules orally (two times) per day

DRUG

Gamma- Glutamylcusteine

400mg capsules orally (three times) per day

DRUG

Gamma- Glutamylcysteine

400mg capsules once a day

Sponsors & Collaborators

  • Robert J. Coury Family - Mylan Foundation

    collaborator UNKNOWN

  • Inid Research Lab

    collaborator UNKNOWN

  • Pravat Mandal

    lead OTHER

Principal Investigators

  • Pravat Mandal, PhD · University of Pittsburgh

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
55 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2027-01-31
Completion
2027-02-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07583251 on ClinicalTrials.gov